Arcutis Biotherapeutics Quarterly Balance Sheet
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics financial position
As of Jun 30, 2026, Arcutis Biotherapeutics reported total assets of $488.5 million, up 38.6% from a year earlier against total liabilities of $268.0 million. Shareholders' equity stood at $220.6 million, or 45.2% of assets. The company held $34.1 million in cash and equivalents against $108.9 million of debt, a net debt position of $74.8 million.
The current ratio (current assets divided by current liabilities) was 2.92, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.49.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 34.12M | 34.76M | 42.91M | 47.12M | 72.74M | 53.10M | 71.33M | 134.85M | 84.27M | 190.10M | 88.39M | 107.47M |
| Short-Term Investments | 204.43M | 189.24M | 178.07M | 143.95M | 118.08M | 144.98M | 156.62M | 195.71M | 278.17M | 213.77M | 183.46M | 119.64M |
| Receivables | 155.16M | 144.38M | 146.23M | 115.12M | 106.69M | 85.42M | 73.07M | 60.12M | 43.41M | 37.15M | 25.81M | 19.42M |
| Inventory | 38.88M | 37.39M | 22.63M | 22.42M | 16.32M | 16.61M | 14.53M | 14.02M | 13.88M | 13.25M | 13.13M | 13.91M |
| Total Current Assets | 467.67M | 438.06M | 411.23M | 349.22M | 332.78M | 323.67M | 335.82M | 423.72M | 434.59M | 468.06M | 330.43M | 281.55M |
| Property, Plant & Equipment | 872.00K | 1.04M | 1.04M | 1.22M | 1.39M | 1.50M | 1.04M | 1.19M | 1.35M | 1.37M | 1.54M | 1.74M |
| Intangible Assets | 13.69M | 14.25M | 14.81M | 15.38M | 15.94M | 16.50M | 9.48M | 9.79M | 6.06M | 6.25M | 6.44M | 6.63M |
| Total Assets | 488.54M | 460.00M | 432.97M | 370.98M | 352.43M | 344.11M | 348.89M | 437.35M | 444.76M | 478.54M | 341.37M | 292.96M |
| Accounts Payable | 6.60M | 18.30M | 12.53M | 5.79M | 15.08M | 24.53M | 14.22M | 19.32M | 7.94M | 12.97M | 11.99M | 13.18M |
| Short-Term Debt | 6.95M | 7.95M | 1.00M | 1.00M | 1.00M | — | 0 | 99.51M | — | — | 0 | — |
| Total Current Liabilities | 160.34M | 163.20M | 129.84M | 99.77M | 103.94M | 91.13M | 81.01M | 172.43M | 51.35M | 47.31M | 46.67M | 41.89M |
| Long-Term Debt | 101.95M | 101.47M | 107.96M | 107.50M | 107.05M | 107.62M | 107.20M | 105.09M | 203.81M | 202.80M | 201.80M | 200.78M |
| Total Liabilities | 267.96M | 270.36M | 243.49M | 212.90M | 213.46M | 201.45M | 191.35M | 280.71M | 258.33M | 253.60M | 252.70M | 246.24M |
| Shareholders' Equity | 220.58M | 189.65M | 189.48M | 158.07M | 138.97M | 142.66M | 157.54M | 156.64M | 186.43M | 224.94M | 88.67M | 46.72M |
| Retained Earnings | -1.13B | -1.15B | -1.14B | -1.16B | -1.16B | -1.15B | -1.12B | -1.11B | -1.07B | -1.02B | -981.90M | -915.62M |
| Total Debt | 108.90M | 109.42M | 108.96M | 108.50M | 108.05M | 107.62M | 107.20M | 204.61M | 203.81M | 202.80M | 201.80M | 200.78M |
| Net Cash (Debt) | 129.65M | 114.58M | 112.02M | 82.57M | 82.77M | 90.47M | 120.75M | 125.95M | 158.63M | 201.06M | 70.06M | 26.33M |
| Shares Outstanding | 125.59M | 125.04M | 123.33M | 120.29M | 119.80M | 119.14M | 117.85M | 117.00M | 116.48M | 115.51M | 96.79M | 61.86M |
This table shows 12 quarterly periods of Arcutis Biotherapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a balance sheet?